2025 Q3 -tulosraportti
88 päivää sitten54 min
3,75 DKK/osake
Viimeisin osinko
3,15%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
1 827 995
Myynti
Määrä
1 832 928
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 85 | - | - | ||
| 85 | - | - | ||
| 16 | - | - | ||
| 69 | - | - | ||
| 85 | - | - |
Ylin
375,75VWAP
Alin
357,5VaihtoMäärä
2 235,3 6 063 807
VWAP
Ylin
375,75Alin
357,5VaihtoMäärä
2 235,3 6 063 807
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 6 063 807 | 6 063 807 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 6 063 807 | 6 063 807 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2. 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11.2025 | |
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| Vuosittainen yhtiökokous 2025 | 27.3.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 t sittenWhy I believe consensus is wrong. The pill can drive many more new users and not high cannibalization The pill dramatically lowers the threshold: no injection, no cooling, discreet use → people feel less like a patient and more like “regular users”. Adoption > conversion: The biggest effect does not come from injection users switching, but from entirely new user groups joining. Identity and psychology are underestimated: The pill is perceived as a lifestyle product, not a medical treatment – this opens up a much larger market. Low stigma leads to high volume growth. New users can increase sharply already in the first year, even if existing patients switch slower. The market models too cautiously, focusing on clinic and price – not human friction and behavior. If this succeeds, consensus estimates are too low, and the upside for Novo in 2027–2028 is significant.
·1 t sittenMorgan Stanley on the earnings season: Points out Norwegian heavyweight as favorite The earnings season in Europe has started strongly, according to Morgan Stanley, which has pointed out potential winners and losers. Points out Novo as the worst performer On the stock strategists' list of which European companies could surprise negatively, healthcare giant Novo Nordisk is the most exposed. Morgan Stanley has an underweight recommendation on the company, which will present figures on Wednesday, February 4. https://www.finansavisen.no/finans/2026/02/02/8325148/morgan-stanley-om-resultatsesongen-peker-ut-norsk-tungvekter-som-favoritt
·2 t sittenBetween two glasses of port wine, I have thoroughly examined the expectations for Novo's upcoming quarterly report, and my best guess is that the market is entering the earnings report with subdued and rather cautious expectations. There is still strong demand for Novo's products, but at the same time, uncertainty about growth in 2026, increased competition, and price pressure in the USA weigh more on the market's mind. This makes the stock vulnerable if guidance disappoints, but also interesting if Novo manages to surprise positively. This is how I see the scenarios. If the earnings report falls short of expectations, the share price could drop due to more cautious guidance. If the figures are in line with expectations, I anticipate a flat to slightly positive reaction. If, on the other hand, there is a positive surprise, especially regarding the pipeline or future prospects, there could be potential for a short-term price increase. My overall assessment is that volatility will be high, and the probability of a flat or slightly negative reaction is greater than for a big rally, unless Novo delivers strong signals about future growth, for example via pipeline and new treatments. As always, one earnings day rarely changes the long-term case, but it can quickly change the sentiment.
·2 t sitten · MuokattuNot many people are talking about Lilly also releasing Q4 on Feb. 4th, as well as guidance for '26. What do you think about that, and what influence can it have on the NOVO share price? Lilly is rising in the USA this evening, where NN is around the Danish close.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
88 päivää sitten54 min
3,75 DKK/osake
Viimeisin osinko
3,15%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenWhy I believe consensus is wrong. The pill can drive many more new users and not high cannibalization The pill dramatically lowers the threshold: no injection, no cooling, discreet use → people feel less like a patient and more like “regular users”. Adoption > conversion: The biggest effect does not come from injection users switching, but from entirely new user groups joining. Identity and psychology are underestimated: The pill is perceived as a lifestyle product, not a medical treatment – this opens up a much larger market. Low stigma leads to high volume growth. New users can increase sharply already in the first year, even if existing patients switch slower. The market models too cautiously, focusing on clinic and price – not human friction and behavior. If this succeeds, consensus estimates are too low, and the upside for Novo in 2027–2028 is significant.
- ·1 t sittenMorgan Stanley on the earnings season: Points out Norwegian heavyweight as favorite The earnings season in Europe has started strongly, according to Morgan Stanley, which has pointed out potential winners and losers. Points out Novo as the worst performer On the stock strategists' list of which European companies could surprise negatively, healthcare giant Novo Nordisk is the most exposed. Morgan Stanley has an underweight recommendation on the company, which will present figures on Wednesday, February 4. https://www.finansavisen.no/finans/2026/02/02/8325148/morgan-stanley-om-resultatsesongen-peker-ut-norsk-tungvekter-som-favoritt
- ·2 t sittenBetween two glasses of port wine, I have thoroughly examined the expectations for Novo's upcoming quarterly report, and my best guess is that the market is entering the earnings report with subdued and rather cautious expectations. There is still strong demand for Novo's products, but at the same time, uncertainty about growth in 2026, increased competition, and price pressure in the USA weigh more on the market's mind. This makes the stock vulnerable if guidance disappoints, but also interesting if Novo manages to surprise positively. This is how I see the scenarios. If the earnings report falls short of expectations, the share price could drop due to more cautious guidance. If the figures are in line with expectations, I anticipate a flat to slightly positive reaction. If, on the other hand, there is a positive surprise, especially regarding the pipeline or future prospects, there could be potential for a short-term price increase. My overall assessment is that volatility will be high, and the probability of a flat or slightly negative reaction is greater than for a big rally, unless Novo delivers strong signals about future growth, for example via pipeline and new treatments. As always, one earnings day rarely changes the long-term case, but it can quickly change the sentiment.
- ·2 t sitten · MuokattuNot many people are talking about Lilly also releasing Q4 on Feb. 4th, as well as guidance for '26. What do you think about that, and what influence can it have on the NOVO share price? Lilly is rising in the USA this evening, where NN is around the Danish close.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
1 827 995
Myynti
Määrä
1 832 928
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 85 | - | - | ||
| 85 | - | - | ||
| 16 | - | - | ||
| 69 | - | - | ||
| 85 | - | - |
Ylin
375,75VWAP
Alin
357,5VaihtoMäärä
2 235,3 6 063 807
VWAP
Ylin
375,75Alin
357,5VaihtoMäärä
2 235,3 6 063 807
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 6 063 807 | 6 063 807 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 6 063 807 | 6 063 807 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2. 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11.2025 | |
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| Vuosittainen yhtiökokous 2025 | 27.3.2025 |
2025 Q3 -tulosraportti
88 päivää sitten54 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2. 3 päivää |
| Menneet tapahtumat | ||
|---|---|---|
| Ylimääräinen yhtiökokous 2025 | 14.11.2025 | |
| 2025 Q3 -tulosraportti | 6.11.2025 | |
| 2025 Q2 -tulosraportti | 7.8.2025 | |
| 2025 Q1 -tulosraportti | 8.5.2025 | |
| Vuosittainen yhtiökokous 2025 | 27.3.2025 |
3,75 DKK/osake
Viimeisin osinko
3,15%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenWhy I believe consensus is wrong. The pill can drive many more new users and not high cannibalization The pill dramatically lowers the threshold: no injection, no cooling, discreet use → people feel less like a patient and more like “regular users”. Adoption > conversion: The biggest effect does not come from injection users switching, but from entirely new user groups joining. Identity and psychology are underestimated: The pill is perceived as a lifestyle product, not a medical treatment – this opens up a much larger market. Low stigma leads to high volume growth. New users can increase sharply already in the first year, even if existing patients switch slower. The market models too cautiously, focusing on clinic and price – not human friction and behavior. If this succeeds, consensus estimates are too low, and the upside for Novo in 2027–2028 is significant.
- ·1 t sittenMorgan Stanley on the earnings season: Points out Norwegian heavyweight as favorite The earnings season in Europe has started strongly, according to Morgan Stanley, which has pointed out potential winners and losers. Points out Novo as the worst performer On the stock strategists' list of which European companies could surprise negatively, healthcare giant Novo Nordisk is the most exposed. Morgan Stanley has an underweight recommendation on the company, which will present figures on Wednesday, February 4. https://www.finansavisen.no/finans/2026/02/02/8325148/morgan-stanley-om-resultatsesongen-peker-ut-norsk-tungvekter-som-favoritt
- ·2 t sittenBetween two glasses of port wine, I have thoroughly examined the expectations for Novo's upcoming quarterly report, and my best guess is that the market is entering the earnings report with subdued and rather cautious expectations. There is still strong demand for Novo's products, but at the same time, uncertainty about growth in 2026, increased competition, and price pressure in the USA weigh more on the market's mind. This makes the stock vulnerable if guidance disappoints, but also interesting if Novo manages to surprise positively. This is how I see the scenarios. If the earnings report falls short of expectations, the share price could drop due to more cautious guidance. If the figures are in line with expectations, I anticipate a flat to slightly positive reaction. If, on the other hand, there is a positive surprise, especially regarding the pipeline or future prospects, there could be potential for a short-term price increase. My overall assessment is that volatility will be high, and the probability of a flat or slightly negative reaction is greater than for a big rally, unless Novo delivers strong signals about future growth, for example via pipeline and new treatments. As always, one earnings day rarely changes the long-term case, but it can quickly change the sentiment.
- ·2 t sitten · MuokattuNot many people are talking about Lilly also releasing Q4 on Feb. 4th, as well as guidance for '26. What do you think about that, and what influence can it have on the NOVO share price? Lilly is rising in the USA this evening, where NN is around the Danish close.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
1 827 995
Myynti
Määrä
1 832 928
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 85 | - | - | ||
| 85 | - | - | ||
| 16 | - | - | ||
| 69 | - | - | ||
| 85 | - | - |
Ylin
375,75VWAP
Alin
357,5VaihtoMäärä
2 235,3 6 063 807
VWAP
Ylin
375,75Alin
357,5VaihtoMäärä
2 235,3 6 063 807
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 6 063 807 | 6 063 807 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 6 063 807 | 6 063 807 | 0 | 0 |